Endpoints News ١٩ ديسمبر ٢٠٢٥ Altimmune advances in MASH; New China obesity biotech; Ipsen Phase 2 fail
Endpoints News ١٩ ديسمبر ٢٠٢٥ Joe Jimenez's Aditum goes to Fosun for major biobuck-loaded collaboration
Endpoints News ١٨ ديسمبر ٢٠٢٥ Daiichi and Merck's I-Dxd lung cancer study faces partial hold due to deaths
Endpoints News ١٨ ديسمبر ٢٠٢٥ After year of triumph, Insmed stumbles with chronic rhinosinusitis fail, brings in new asset
Endpoints News ١٨ ديسمبر ٢٠٢٥ Lilly’s orforglipron is the first oral obesity therapy to show its worth in the maintenance setting
Endpoints News ١٨ ديسمبر ٢٠٢٥ Steve Paul's post-Karuna act draws $165M to schizophrenia biotech Syremis